Skip to main navigation

Vivek Ramaswamy

Founder & CEO

Roivant Sciences

OUR STORY
OUR PIPELINE
OUR PEOPLE
ROIVANT DISCOVERY
INVESTOR RELATIONS +
JOIN US

Press Releases

Year

August 3, 2022

Roivant Sciences to Report Financial Results for the Quarter Ended June 30, 2022 on Monday, August 15, 2022

June 28, 2022

Roivant Sciences Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 and Provides Business Update

June 28, 2022

Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus

June 15, 2022

Roivant Sciences to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 on Tuesday, June 28, 2022

May 24, 2022

FDA Approves Dermavant’s VTAMA® (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults: First Topical Novel Chemical Entity Launched for Psoriasis in the U.S. in 25 Years

May 19, 2022

Roivant to Present at Upcoming Investor Conferences

May 16, 2022

Aruvant Announces Oral Presentation at American Society of Gene and Cell Therapy (ASGCT)

May 2, 2022

Roivant Appoints Chief Development Officer and Announces Multiple Collaborations in Targeted Protein Degradation

March 25, 2022

Dermavant Showcases New Long-Term Durability and Tolerability Data from Phase 3 PSOARING 3 Trial of Tapinarof Cream for Adults with Plaque Psoriasis at the 2022 AAD Annual Meeting

March 11, 2022

Roivant to Present at Targeted Protein Degradation Conference

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 15

Print Page
Email Alerts
RSS Feeds
IR Contacts

© 2022 Roivant Sciences Ltd.

Careers Privacy Policy

Follow us on LinkedIn